Treatment of Cancer-Related Anemia
APA 6th Edition
Badžek, S., Curić, Z., Krajina, Z., Pleština, S., Golubić-Ćepulić, B. & Radman, I. (2008). Treatment of Cancer-Related Anemia. Collegium antropologicum, 32 (2), 615-622. Retrieved from https://hrcak.srce.hr/27205
MLA 8th Edition
Badžek, Saša, et al. "Treatment of Cancer-Related Anemia." Collegium antropologicum, vol. 32, no. 2, 2008, pp. 615-622. https://hrcak.srce.hr/27205. Accessed 1 Oct. 2023.
Chicago 17th Edition
Badžek, Saša, Zvonimir Curić, Zdenko Krajina, Stjepko Pleština, Branka Golubić-Ćepulić and Ivo Radman. "Treatment of Cancer-Related Anemia." Collegium antropologicum 32, no. 2 (2008): 615-622. https://hrcak.srce.hr/27205
Badžek, S., et al. (2008). 'Treatment of Cancer-Related Anemia', Collegium antropologicum, 32(2), pp. 615-622. Available at: https://hrcak.srce.hr/27205 (Accessed 01 October 2023)
Badžek S, Curić Z, Krajina Z, Pleština S, Golubić-Ćepulić B, Radman I. Treatment of Cancer-Related Anemia. Collegium antropologicum [Internet]. 2008 [cited 2023 October 01];32(2):615-622. Available from: https://hrcak.srce.hr/27205
S. Badžek, Z. Curić, Z. Krajina, S. Pleština, B. Golubić-Ćepulić and I. Radman, "Treatment of Cancer-Related Anemia", Collegium antropologicum, vol.32, no. 2, pp. 615-622, 2008. [Online]. Available: https://hrcak.srce.hr/27205. [Accessed: 01 October 2023]
Anemia with consequent tissue hypoxia is common problem in cancer patients. Developed via various patophysiological
mechanisms, it has deleterious effect on quality of life and survival of patients with cancer. Recognition of symptoms
and timely initiation of treatment improve patients’ quality of life, as well as efficacy of oncological treatment. Red blood
cells transfusions are well known and efficient way of anemia correction. They are »golden standard« in treatment of
cancer-related anemia today, and are unavoidable in almost all patients with hemoglobin concentration below 80 g/L.
Newest therapy guidelines in developed countries, supported by recent literature, encourage use of recombinant human
erythropoietin (rHu-EPO), although detailed meta-analyses and prospective randomized clinical trials have shown that
rHu-EPO decreases the need for transfusions in only 9–45% patients with cancer, only if they have mild anemia. rHu-EPO
increases incidence of thromboembolic events, and suspicion arises that it supports tumor cells growth and multiplication.
Therefore, it is necessary to define subgroups of patients which are best candidates for rHu-EPO therapy, to accomplish
lower intensity of transfusion therapy.
Visits: 1.050 *